Effect of psychopharmacological combinations on psychopathological symptom burden and BMI trajectories in patients with eating disorders

Prospective monitoring of BMI and AMI revealed differential associations between psychopharmacological agents and both nutritional and symptomatic trajectories in an inpatient ED cohort predominantly composed of patients with AN. Mood stabilizers were associated with smaller BMI increases, while several antidepressants corresponded to less improvement in psychopathological symptom burden. Atypical antipsychotics showed the strongest prospective reductions in AMI. These findings highlight the value of prospective, real-world monitoring to inform pharmacological strategies in treatment-resistant eating disorders.